Vladonix (A-6) (10mg capsule)
Vladonix (code A-6) is a Khavinson-family peptide bioregulator of the thymus gland (a 'Cytomax'), in oral capsule form. It is not an approved drug; it is sold as a supplement. This page summarizes literature/research data strictly for research-use context.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Vladonix is a peptide bioregulator ('Cytomax') of the thymus gland. Per the Khavinson peptide literature, such short peptides are studied as tissue-specific regulators of gene expression and cell differentiation. For the thymus, research focuses on T-lymphocyte maturation and T/B-cell balance. The thymus undergoes age-related involution, which makes thymic peptides relevant to immunosenescence research. Data come predominantly from Russian research and there is no substantial international clinical validation.
Quick Start
- Form: oral capsules (~10 mg of thymus peptides per capsule) — no reconstitution needed.
- Manufacturer reference protocol: intensive course 2 capsules/day × 30 days, with meals.
- Target: thymus gland → studied for immune-function regulation (T-lymphocyte maturation).
- Regulatory status: a supplement, not an approved drug in the EU/US; evidence is predominantly Russian.
Vladonix reference protocol (as stated by manufacturer/distributors)
Route: Oral (per os), with meals | Frequency: Daily intake in courses (course-based)
| Week | Dose | Amount |
|---|---|---|
| Intensive course (30 days) | 2 capsules/day | 60 capsules total |
| Maintenance (each following month, 10 days) | 2 capsules/day | 20 capsules |
| General reference | 1–2 capsules, 1–2× per day | with meals |
The table values are reported product regimens (manufacturer/distributors) and are NOT medical advice or usage instructions. The product is a supplement, not an approved drug.
Related compounds
Protocol Overview
- Product: Vladonix (code A-6), a thymus peptide bioregulator ('Cytomax'), Khavinson family / St. Petersburg Institute of Bioregulation and Gerontology.
- Composition: a complex of low-molecular-weight peptides (MW <10,000 Da) isolated from the thymus of young calves (bovine origin), ~10 mg per capsule.
- Regulatory status: studied mainly in Russia; not an FDA/EMA-approved drug — sold as a supplement.
- Injectable counterpart: Thymalin (same thymus target, injectable form).
Dosing Protocol
- Intensive course: 2 capsules/day for 30 days, with meals (as stated).
- Maintenance: 2 capsules/day for 10 days each following month.
- Repetition: courses are typically repeated 1–2 times/year per product instructions.
- Interpretation: these are reported product regimens, not medical advice or a dosing plan.
- Break between cycles: A 2–4 week break is recommended before repeating the cycle.
Washout & Cycle Restart
When can I restart?
After completing the cycle, a 2–4 week break is recommended before starting a new cycle. This allows the body to restore normal function and prevents potential downregulation (tachyphylaxis).
Storage Instructions
- Store in a cool, dry place away from direct sunlight, per the product label.
Important Notes
- Vladonix is a supplement, not an FDA/EMA-approved drug.
- Evidence is predominantly Russian; international peer-reviewed clinical validation is limited.
- This is educational/research information and not medical advice.
Regulatory Status
This is educational/research information and not medical advice.
Potential Benefits & Side Effects
Potential Benefits:
- Research interest: regulation of immune function via the thymus (T-lymphocyte maturation).
- Context: studied in the field of immunosenescence and thymic involution.
- Research status: international clinical validation is required before any conclusions.
Potential Side Effects:
- The safety profile is not established by large-scale international clinical data.
- As a bovine-derived product, individuals with relevant allergies/sensitivities should take this into account.
- Any supplement use should be discussed with a healthcare professional.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Limited international safety data
Vladonix is sold as a supplement and its evidence base is predominantly Russian. Large international clinical datasets establishing its long-term safety profile are unavailable.
📄 Molecules 2021 — Khavinson peptide regulation reviewReferences
- Int J Mol Sci (2023) — Thymalin (KE/EW peptides) and gene expression — Khavinson thymic peptides
View Source - Molecules (2021) — Peptide Regulation of Gene Expression — systematic review (Khavinson)
View Source - Stem Cell Rev Rep (2020) — Peptide Regulation of Cell Differentiation (Khavinson)
View Source - Aging Cell (2022) — Age-related thymic involution — mechanisms and functional impact (independent background)
View Source
External Sources & Regulatory Status
Regulatory Approvals
Supplement — No FDA/EMA approval; the literature is mainly Russian
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →